CL2021001307A1 - Anticuerpos antiestafilococo y usos de estos - Google Patents

Anticuerpos antiestafilococo y usos de estos

Info

Publication number
CL2021001307A1
CL2021001307A1 CL2021001307A CL2021001307A CL2021001307A1 CL 2021001307 A1 CL2021001307 A1 CL 2021001307A1 CL 2021001307 A CL2021001307 A CL 2021001307A CL 2021001307 A CL2021001307 A CL 2021001307A CL 2021001307 A1 CL2021001307 A1 CL 2021001307A1
Authority
CL
Chile
Prior art keywords
antibodies
antigen
compositions
binding fragments
staphylococcal
Prior art date
Application number
CL2021001307A
Other languages
English (en)
Inventor
Christos Kyratsous
Anna Zumsteg
Brinda Prasad
Alida Coppi
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2021001307A1 publication Critical patent/CL2021001307A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos sometidos a especiación o fragmentos de unión al antígeno que se unen a antígenos estafilocócicos, donde los anticuerpos y fragmentos de unión al antígeno tienen unión de Fc atenuada a la Proteína A o proteína homóloga. También se proporcionan composiciones que comprenden los anticuerpos y métodos de uso. Los anticuerpos y composiciones son útiles para tratar la infección estafilocócica, reducir los títulos bacterianos en suero o riñón y tratar los síntomas asociados con la infección estafilocócica. Los anticuerpos también pueden prevenir la gravedad y/o duración de la enfermedad primaria.
CL2021001307A 2018-11-21 2021-05-19 Anticuerpos antiestafilococo y usos de estos CL2021001307A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862770608P 2018-11-21 2018-11-21
US201962822029P 2019-03-21 2019-03-21
US201962865436P 2019-06-24 2019-06-24

Publications (1)

Publication Number Publication Date
CL2021001307A1 true CL2021001307A1 (es) 2021-11-05

Family

ID=68848487

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021001307A CL2021001307A1 (es) 2018-11-21 2021-05-19 Anticuerpos antiestafilococo y usos de estos
CL2023003084A CL2023003084A1 (es) 2018-11-21 2023-10-17 Anticuerpos antiestafilococo y usos de estos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023003084A CL2023003084A1 (es) 2018-11-21 2023-10-17 Anticuerpos antiestafilococo y usos de estos

Country Status (16)

Country Link
US (2) US12024556B2 (es)
EP (1) EP3883963A1 (es)
JP (1) JP2022512904A (es)
KR (1) KR20210093856A (es)
CN (1) CN112867732A (es)
AU (1) AU2019384790A1 (es)
BR (1) BR112021005522A2 (es)
CA (1) CA3110377A1 (es)
CL (2) CL2021001307A1 (es)
CO (1) CO2021003752A2 (es)
IL (1) IL281056A (es)
MA (1) MA55134A (es)
MX (1) MX2021005863A (es)
PH (1) PH12021550538A1 (es)
SG (1) SG11202102060PA (es)
WO (1) WO2020106814A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
US7488807B2 (en) * 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2012122533A2 (en) 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
ME02288B (me) 2010-02-08 2016-02-20 Regeneron Pharma Miš sa zajedničkim lakim lancem
EP2793944A4 (en) * 2011-12-23 2015-09-02 Nicholas B Lydon IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
SG10201701831VA (en) 2012-09-12 2017-05-30 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US10781246B2 (en) 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
WO2019067682A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING TO TARGET STAPHYLOCOCCUS ANTIGEN AND COMPONENT COMPONENT, AND USES THEREOF

Also Published As

Publication number Publication date
SG11202102060PA (en) 2021-03-30
EP3883963A1 (en) 2021-09-29
KR20210093856A (ko) 2021-07-28
US20240301041A1 (en) 2024-09-12
US20200157193A1 (en) 2020-05-21
BR112021005522A2 (pt) 2021-06-29
AU2019384790A1 (en) 2021-03-18
CN112867732A (zh) 2021-05-28
WO2020106814A1 (en) 2020-05-28
CO2021003752A2 (es) 2021-04-19
MX2021005863A (es) 2021-07-16
MA55134A (fr) 2021-09-29
CA3110377A1 (en) 2020-05-28
US12024556B2 (en) 2024-07-02
CL2023003084A1 (es) 2024-04-12
PH12021550538A1 (en) 2022-02-21
JP2022512904A (ja) 2022-02-07
IL281056A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AR121522A1 (es) ANTICUERPOS CONTRA SARS-Cov-2 (SARS2, COVID-19)
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA201792221A1 (ru) Антитела против сортилина и способы их применения
BR112018067458A2 (pt) anticorpos para tigit
ECSP17054182A (es) Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
CL2023003084A1 (es) Anticuerpos antiestafilococo y usos de estos
CL2008003361A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composicones medias que los comprenden.
CO2022002001A2 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
BR112014021477A2 (pt) anticorpos para metaloproteinase de matriz 9
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201990222A1 (ru) Антитела к o2 и пути их применения
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
WO2016145385A3 (en) Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
BR112022020410A2 (pt) Anticorpos anti-phf-tau e usos dos mesmos
PE20230602A1 (es) Anticuerpos anti-sea de muc1
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
CL2022003296A1 (es) Anticuerpos anti-cd200r1 y métodos de uso de los mismos
EA201891800A1 (ru) Антитела к цитруллинированным hla-полипептидам и их применение